These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 28855356)
1. Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. Heery CR; Palena C; McMahon S; Donahue RN; Lepone LM; Grenga I; Dirmeier U; Cordes L; Marté J; Dahut W; Singh H; Madan RA; Fernando RI; Hamilton DH; Schlom J; Gulley JL Clin Cancer Res; 2017 Nov; 23(22):6833-6845. PubMed ID: 28855356 [No Abstract] [Full Text] [Related]
2. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065 [TBL] [Abstract][Full Text] [Related]
3. Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3). Shankar P; Schlom J; Hodge JW Vaccine; 2001 Dec; 20(5-6):744-55. PubMed ID: 11738738 [TBL] [Abstract][Full Text] [Related]
4. Vaccine therapy of established tumors in the absence of autoimmunity. Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742 [TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells. Litzinger MT; Foon KA; Tsang KY; Schlom J; Palena C Leuk Res; 2010 Oct; 34(10):1351-7. PubMed ID: 20122733 [TBL] [Abstract][Full Text] [Related]
6. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Hodge JW; Grosenbach DW; Rad AN; Giuliano M; Sabzevari H; Schlom J Vaccine; 2001 May; 19(25-26):3552-67. PubMed ID: 11348723 [TBL] [Abstract][Full Text] [Related]
7. A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines. Schlom J; Sabzevari H; Grosenbach DW; Hodge JW Artif Cells Blood Substit Immobil Biotechnol; 2003 May; 31(2):193-228. PubMed ID: 12751840 [TBL] [Abstract][Full Text] [Related]
9. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725 [TBL] [Abstract][Full Text] [Related]
10. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Aarts WM; Schlom J; Hodge JW Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537 [TBL] [Abstract][Full Text] [Related]
11. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691 [TBL] [Abstract][Full Text] [Related]
12. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322 [TBL] [Abstract][Full Text] [Related]
13. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas. Duggan MC; Jochems C; Donahue RN; Richards J; Karpa V; Foust E; Paul B; Brooks T; Tridandapani S; Olencki T; Pan X; Lesinski GB; Schlom J; Carson Iii WE Cancer Immunol Immunother; 2016 Nov; 65(11):1353-1364. PubMed ID: 27581603 [TBL] [Abstract][Full Text] [Related]
14. Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. Collins JM; Donahue RN; Tsai YT; Manu M; Palena C; Gatti-Mays ME; Marté JL; Madan RA; Karzai F; Heery CR; Strauss J; Abdul-Sater H; Cordes L; Schlom J; Gulley JL; Bilusic M Oncologist; 2020 Jul; 25(7):560-e1006. PubMed ID: 31876334 [TBL] [Abstract][Full Text] [Related]
15. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Zhu M; Terasawa H; Gulley J; Panicali D; Arlen P; Schlom J; Tsang KY Cancer Res; 2001 May; 61(9):3725-34. PubMed ID: 11325845 [TBL] [Abstract][Full Text] [Related]
16. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. Hodge JW; Rad AN; Grosenbach DW; Sabzevari H; Yafal AG; Gritz L; Schlom J J Natl Cancer Inst; 2000 Aug; 92(15):1228-39. PubMed ID: 10922408 [TBL] [Abstract][Full Text] [Related]
17. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Hamilton DH; Litzinger MT; Jales A; Huang B; Fernando RI; Hodge JW; Ardiani A; Apelian D; Schlom J; Palena C Oncotarget; 2013 Oct; 4(10):1777-90. PubMed ID: 24125763 [TBL] [Abstract][Full Text] [Related]
18. Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients. Litzinger MT; Foon KA; Sabzevari H; Tsang KY; Schlom J; Palena C Cancer Immunol Immunother; 2009 Jun; 58(6):955-65. PubMed ID: 19009294 [TBL] [Abstract][Full Text] [Related]
19. A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. Gatti-Mays ME; Strauss J; Donahue RN; Palena C; Del Rivero J; Redman JM; Madan RA; Marté JL; Cordes LM; Lamping E; Orpia A; Burmeister A; Wagner E; Pico Navarro C; Heery CR; Schlom J; Gulley JL Clin Cancer Res; 2019 Aug; 25(16):4933-4944. PubMed ID: 31110074 [TBL] [Abstract][Full Text] [Related]
20. Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors. Rad AN; Schlom J; Hodge JW Crit Rev Oncol Hematol; 2001; 39(1-2):43-57. PubMed ID: 11418301 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]